Category: Lawsuit
Opportunity: Data analysis companies can use this incident to help convince potential customers of the importance of the quality of their data analysis partner
Company: Galera Therapeutics
Product/Asset: Avasopasem
Issue: Incorrect analysis of clinical trial data
Latest trigger event for Opp: May 30, 2023 SEC filing by Galera Therapeutics
Target Companies: Clinical data analysis services and software companies, CROs
Details:
On May 30, 2023, Galera Therapeutics filed a lawsuit against Alira Health Clinical and IQVIA Biotech alleging breach of contract and negligence specifically related to an error by the CROs in 2021 in the statistical program for the Phase 3 ROMAN trial of avasopasem for the reduction of severe oral mucositis (“SOM”) induced by radiotherapy in patients with locally advanced head and neck cancer. In December 2021, Galera announced that the error in the statistical program for the Phase 3 ROMAN trial had been detected. Correction of this error yielded the correct, statistically significant p-values for the primary endpoint and a key secondary endpoint of the Phase 3 ROMAN trial. This litigation is in its early stages and Galera is seeking damages.
In February 2023, the FDA accepted and granted Priority Review designation to the NDA for Avasopasem for the reduction of SOM induced by radiotherapy and PDUFA target date is August 9, 2023.
About Galera Therapeutics
Company Type: Public Company
Market Cap (7/18/23): $128,700,000
Location: Malvern, Pennsylvania
Cash (Q1 2023): $47,750,000
Burn rate/quarter: $-10,930,000
Technology Focus: Small Molecule
Latest stage asset: PDUFA Approval Decision
Indications: Severe oral mucositis (SOM)
Next readout: August 9, 2023
Key employees: Subscribe to learn more!
💡 Do you sell your products or services to biopharma companies? 💡
BiopharmIQ MarketCompass is a market intelligence tool to help with your business development. Get a free sample report of potential targets.
Article History:
Originally posted 7/19/23 (RB)
Kommentare